Inventor · disambiguated record
Krishnaswamy Yeleswaram
Also filed as: YELESWARAM KRISHNASWAMY
20 granted patents·12 pending applications·188 citations·filing 2004–2025
95Inventor score
Top patents by PatentIndex Score
32 records- 0197US11628162B2Methods of treating cancer with an FGFR inhibitorINCYTE CORP·Filed 2020·Granted Apr 18, 2023·7 cites·11 claims
- 0297US11337927B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2020·Granted May 24, 2022·12 cites·34 claims
- 0397US11219624B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2020·Granted Jan 11, 2022·10 cites·12 claims
- 0497US10874616B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2018·Granted Dec 29, 2020·17 cites·36 claims
- 0597US10869870B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2020·Granted Dec 22, 2020·10 cites·29 claims
- 0696US10166191B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2013·Granted Jan 1, 2019·32 cites·12 claims
- 0795US11590136B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2022·Granted Feb 28, 2023·2 cites·27 claims
- 0895US11045421B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2020·Granted Jun 29, 2021·11 cites·48 claims
- 0995US10758543B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2019·Granted Sep 1, 2020·14 cites·20 claims
- 1094US11571425B2Topical formulation for a JAK inhibitorINCYTE CORP·Filed 2022·Granted Feb 7, 2023·2 cites·28 claims
- 1194US9655854B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2014·Granted May 23, 2017·55 cites·31 claims
- 1292US10561616B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2017·Granted Feb 18, 2020·15 cites·18 claims
- 1390US12226419B2Topical formulation for a JAK inhibitorINCYTE HOLDINGS CORP·Filed 2024·Granted Feb 18, 2025·0 cites·20 claims
- 1490US2025064746A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2024·Application pending·0 cites
- 1587US2025312279A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2025·Application pending·0 cites
- 1686US11896717B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 13, 2024·0 cites·23 claims
- 1785US2023277541A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 1884US2025127724A1Sustained release dosage forms for a jak1 inhibitorINCYTE CORP·Filed 2024·Application pending·0 cites
- 1983US11596632B2JAK1 pathway inhibitors for the treatment of gastrointestinal diseaseINCYTE CORP·Filed 2019·Granted Mar 7, 2023·1 cites·18 claims
- 2083US11576865B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 2182US11576864B2Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 2280US2022211631A1Sustained-release dosage forms of ruxolitinibINCYTE CORP·Filed 2022·Application pending·0 cites
- 2379US2022211707A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2021·Application pending·0 cites
- 2474US12151026B2Sustained release dosage forms for a JAK1 inhibitorINCYTE CORP·Filed 2021·Granted Nov 26, 2024·0 cites·18 claims
- 2573US12150943B2JAK1 pathway inhibitors for the treatment of gastrointestinal diseaseINCYTE CORP·Filed 2023·Granted Nov 26, 2024·0 cites·7 claims
- 2671US2023218591A1Methods of treating cancer with an fgfr inhibitorINCYTE CORP·Filed 2023·Application pending·0 cites
- 2760US2015250790A1Topical formulation for a jak inhibitorINCYTE CORP·Filed 2015·Application pending·0 cites
- 2859US2011288107A1Topical formulation for a jak inhibitorPARIKH BHAVNISH·Filed 2011·Application pending·0 cites
- 2956US2005244490A1Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapyOTTO MICHAEL·Filed 2004·Application pending·0 cites
- 3054US12226418B2Dosing regimen for the treatment of PI3K related disordersINCYTE CORP·Filed 2019·Granted Feb 18, 2025·0 cites·45 claims
- 3154US2020179347A1Pharmaceutical compositions and methods for indoleamine, 2, 3-dioxygenase inhibition and indications thereforINCYTE CORP·Filed 2020·Application pending·0 cites
- 3244US2018353483A1Pharmaceutical compositions and methods for indoleamine, 2, 3-dioxygenase inhibition and indications thereforINCYTE CORP·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Krishnaswamy Yeleswaram files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →